Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

Mise à jour : Il y a 4 ans
Référence : NCT01719380

Femme et Homme

Extrait

This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer


Critère d'inclusion

  • Colorectal Cancer